Ciliotherapy: A novel intervention in polycystic kidney disease

Journal of Geriatric Cardiology

Volumn 11, Issue 1, 2014, Pages 63-73

  Kathem, Sarmed H ^a,b   Mohieldin, Ashraf M ^a   Abdul Majeed, Shakila ^a   Ismail, Sajida H ^b   Altaei, Qaiss H ^c   Alshimmari, Ibrahim K ^d   Alsaidi, Mohanned M ^d   Khammas, Hussein ^d   Nauli, Andromeda M ^e   Joe, Bina ^a   Nauli, Surya M ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF BAGHDAD   (Iraq)

^c Kidney Disease and Transplant Center Medical City Complex   (Iraq)

^d Alkadhumia Academic Hospital   (Iraq)

^e CALIFORNIA NORTHSTATE UNIVERSITY   (United States)

Author keywords

Blood pressure; Chemosensor; Fluid shear stress; Mechanosensor; Mechanotransduction; Primary cilium

Indexed keywords

CREATININE; DOMPERIDONE; DOPAMINE 3 RECEPTOR; DOPAMINE 5 RECEPTOR; FENOLDOPAM; LEVODOPA; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PEROXYNITRITE; POLYCYSTIN 1; SUPEROXIDE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL TONE; CILIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; EUKARYOTIC FLAGELLUM; FEMALE; FOLLOW UP; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY POLYCYSTIC DISEASE; MALE; MEAN ARTERIAL PRESSURE; MOLECULAR THERAPY; MOUSE; MULTICENTER STUDY; NONHUMAN; PROTEIN BLOOD LEVEL; STEADY STATE; TREATMENT DURATION;

EID: 84902282285     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1671-5411.2014.01.001     Document Type: Article

References (21)

1. Kelleher CL, McFann KK, Johnson AM, et al. Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population. Am J Hypertens 2004; 17: 1029-1034. (Pubitemid 39469325)
2. Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 2003; 33: 129-137. (Pubitemid 36177063)
3. Xu C, Rossetti S, Jiang L, et al. Human ADPKD primary cyst epithelial cells with a novel, single codon deletion in the PKD1 gene exhibit defective ciliary polycystin localization and loss of flow-induced Ca2+ signaling. Am J Physiol Renal Physiol 2007; 292: 930-945.
4. Abdul-Majeed S, Moloney BC, Nauli SM. Mechanisms regulating cilia growth and cilia function in endothelial cells. Cell Mol Life Sci 2012; 69: 165-173.
5. AbouAlaiwi WA, Takahashi M, Mell BR, et al. Ciliary polycystin-2 is a mechanosensitive calcium channel involved in nitric oxide signaling cascades. Circ Res 2009; 104: 860-869.
6. Nauli SM, Kawanabe Y, Kaminski JJ, et al. Endothelial cilia are fluid shear sensors that regulate calcium signaling and nitric oxide production through polycystin-1. Circulation 2008; 117: 1161-1171. (Pubitemid 351544064)
7. AbouAlaiwi WA, Ratnam S, Booth RL, et al. Endothelial cells from humans and mice with polycystic kidney disease are characterized by polyploidy and chromosome segregation defects through survivin down-regulation. Hum Mol Genet 2011; 20: 354-367.
8. Abdul-Majeed S, Nauli SM. Dopamine receptor type 5 in the primary cilia has dual chemo- and mechano-sensory roles. Hypertension 2011; 58: 325-331.
9. Takakura A, Contrino L, Beck AW, et al. Pkd1 inactivation induced in adulthood produces focal cystic disease. J Am Soc Nephrol 2008; 19: 2351-2363.
10. Zhang MZ, Yao B, Fang X, et al. Intrarenal dopaminergic system regulates renin expression. Hypertension 2009; 53: 564-570.
11. Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009; 20: 205-212.
12. Ravine D, Gibson RN, Walker RG, et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994; 343: 824-827. (Pubitemid 24147512)
13. Saito I, Kawabe H, Hasegawa C, et al. Effect of L-dopa in young patients with hypertension. Angiology 1991; 42: 691-695.
14. Nishiyama S, Kanno K, Yamaguchi I. Comparison of cardiorenal and emetic effects of dopamine prodrugs docarpamine (TA-870) and levodopa in dogs. J Pharmacobiodyn 1991; 14: 120-125.
15. th ed; The McGraw-Hill Companies, Inc.: New York, USA, 2011.
16. Barendregt JN, Florijn KW, Muizert Y, et al. Borderline hypertensive autosomal dominant polycystic kidney disease patients have enhanced production of renal dopamine. Normalization of renal haemodynamics by DOPA infusion. Nephrol Dial Transplant 1995; 10: 1332-1341.
17. Brookes ZL, Ruff L, Upadhyay VS, et al. Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone. Am J Physiol Heart Circ Physiol 2013; 304: H33-H41.
18. Antoniades C, Demosthenous M, Tousoulis D, et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension 2011; 58: 93-98.
19. Juonala M, Viikari JS, Alfthan G, et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation 2007; 116: 1367-1373. (Pubitemid 47417562)
20. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032-2037.
21. Elkayam U, Ng TM, Hatamizadeh P, et al. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation 2008; 117: 200-205.